SCHEMBL27111163

SCHEMBL27111163

C/C=C(/Cn1c(CCl)nc2ccc(C(=O)OC)cc21)N(C)CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACSS2 Q9NR19 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.41
▸ DRD2 P14416 2/20 0.38
▸ TBXA2R P21731 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PTGER4 P35408 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ TP53 P04637 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ CFTR P13569 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27117221 0.90 ACSS2 (0.44) ACSS2KDM4EDRD2TBXA2RLMNA
SCHEMBL31413142 0.82 ACSS2 (0.49) ACSS2KDM4EDRD2TBXA2RLMNA
SCHEMBL24265281 0.78 ACSS2 (0.49) ACSS2KDM4EDRD2TBXA2RPTGDR2
SCHEMBL20280108 0.76 TLR7 (0.48) ACSS2KDM4EDRD2TBXA2RPTGER4
SCHEMBL29559474 0.76 TLR7 (0.48) ACSS2KDM4EDRD2TBXA2RPTGER4
SCHEMBL31143264 0.76 TP53 (0.50) ACSS2KDM4EDRD2TBXA2RCNR2
Hydrochloric Acid SCHEMBL20266404 0.76 TLR7 (0.47) ACSS2KDM4EDRD2TBXA2RPTGER4
SCHEMBL30474209 0.76 TLR7 (0.48) ACSS2KDM4EDRD2TBXA2RLMNA
SCHEMBL31202954 0.75 ACSS2 (0.46) ACSS2KDM4EDRD2TBXA2RLMNA
SCHEMBL25767043 0.75 ACSS2 (0.46) ACSS2KDM4EDRD2TBXA2RCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2024-02-29 — — US disclosed
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2024-02-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS GLP1R, GIPR, GCGR ACSS2 2661/4885KDM4E 2712/4885DRD2 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback